Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | RET V804L |
Gene Variant Detail | |
Relevant Treatment Approaches | RET Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
RET V804L | Advanced Solid Tumor | sensitive | RET Inhibitor | Ponatinib | Preclinical | Actionable | In a preclinical study, transformed human cell lines expressing RET V804L demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235). | 23811235 |
RET V804L | Advanced Solid Tumor | resistant | RET Inhibitor | Vandetanib | Preclinical | Actionable | In a preclinical study, transformed cells expressing RET V804L demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865). | 15184865 |
RET V804L | Advanced Solid Tumor | predicted - sensitive | RET Inhibitor | Pz-1 | Preclinical | Actionable | In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804L (PMID: 26126987). | 26126987 |
RET V804L | medullary thyroid carcinoma | sensitive | RET Inhibitor | Selpercatinib | Case Reports/Case Series | Actionable | In a Phase I/II trial (LIBRETTO-001), Retevmo (selpercatinib) treatment resulted in an objective response in three patients (3/5) and stable disease in two patients (2/5) with medullary thyroid cancer harboring RET V804L or RET V804M who had been treated previously (PMID: 32846061; NCT03157128). | 32846061 |
RET V804L | Advanced Solid Tumor | predicted - sensitive | RET Inhibitor | APS03118 | Preclinical - Biochemical | Actionable | In a preclinical study, APS03118 inhibited the enzymatic activity of RET V804L in an in vitro assay (J Clin Oncol 40, no. 16_suppl (June 1, 2022)). | detail... |
RET V804L | Advanced Solid Tumor | predicted - sensitive | RET Inhibitor | TY-1091 | Preclinical - Biochemical | Actionable | In a preclinical study, TY-1091 inhibited activity in a cell line expressing RET V804L in culture (Cancer Res (2023) 83 (7_Supplement): 3419). | detail... |